Skip to main
BIOA

BIOA Stock Forecast & Price Target

BIOA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Bioage Labs is a promising clinical-stage biopharmaceutical company focused on developing treatments for metabolic diseases by targeting the biology of human aging, with a technology platform and differentiated human datasets that enable the identification of key targets. With strong potential in their lead candidate BGE-102, currently in Phase 2 development for cardiovascular risk reduction and diabetic macular edema, and promising drug discovery collaborations with major pharmaceutical companies, Bioage has a solid foundation for future growth and success.

Bears say

Bioage Labs is facing several challenges, including a lack of clarity on how their product candidates will ultimately be successful in reducing cardiovascular risk, a potential overlap with existing drugs in their target space, and unknown potential adverse effects on lipids. Additionally, further analysis from their ZEUS trial may be necessary in order to inform a strong Phase 3 program and commercialization plan. Furthermore, the company's reliance on its proprietary data platform and lack of clear commercialization strategy may limit its potential for growth and make it difficult to compete with established players in the market. Overall, the company's uncertainty in its approach and lack of concrete results make it a risky investment option.

BIOA has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioAge Labs Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioAge Labs Inc. (BIOA) Forecast

Analysts have given BIOA a Buy based on their latest research and market trends.

According to 8 analysts, BIOA has a Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioAge Labs Inc. (BIOA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.